CT1812 is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It functions as a sigma-2 receptor antagonist, which is believed to play a role in modulating cellular pathways involved in neurodegeneration. By targeting this receptor, CT1812 aims to protect neurons from toxic amyloid-beta oligomers, which are implicated in the progression of Alzheimer's. Early-stage clinical trials have shown promise in improving cognitive function and slowing disease progression. Additionally, its mechanism of action is being explored for potential applications in other neurological disorders characterized by protein misfolding and neuronal damage.